Ind-Swift Laboratories Ltd.

BSE: INDSWFTLAB532305ISIN INE915B01019

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹371.65+28.90 (+8.43%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹426.00
52W low: ₹87.00
Off 52W high: -12.76%
1M return: -3.20%
3M return: +60.99%
6M return: +157.29%
1Y return: +265.08%
20D avg volume: 55,513
50 DMA: ₹371.64
200 DMA: ₹218.92

Key ratios Consolidated

Market cap: ₹3,232 Cr
Current price: ₹371.65
52W high / low: ₹426.00 / ₹87.00
Face value: ₹10.00
P/E: 38.68
P/B: 2.19
EPS (TTM): ₹9.61
Book value / share: ₹169.54
ROE: —
ROCE: 3.60%
Operating margin: —
Net margin: —
Debt / equity: 0.01
Net debt: ₹-411.94 Cr
Interest cover: 35.79
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 114.2 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	240.46	191.45	169.79	150.85	152.64	152.73	138.24	8.66	11.96	33.17	393.33	287.51
	7.60	7.65	2.22	27.58	17.86	14.58	4.46	13.81	13.01	11.14	25.25	7.11
	248.06	199.11	172.01	178.43	170.50	167.32	142.69	22.48	24.96	44.31	418.58	294.63
	204.11	166.31	154.90	156.19	160.16	156.96	128.11	23.56	24.38	43.33	431.84	270.85
	92.87	81.76	74.20	66.03	66.10	65.40	16.25	5.85	7.81	2.13	247.98	163.10
	16.14	13.50	7.26	9.85	11.89	8.66	33.91	0.37	0.50	25.18	21.20	1.76
	37.97	39.56	37.22	31.95	36.27	32.53	31.32	6.70	5.80	6.09	39.25	37.08
	1.33	0.71	2.44	0.67	2.02	1.15	-26.76	0.11	0.41	0.17	11.47	21.05
	7.77	7.58	8.12	8.84	6.98	6.68	7.44	0.25	0.22	0.25	12.67	13.56
	50.51	40.13	50.52	44.48	37.25	43.51	58.41	—	9.63	9.51	78.25	43.31
	43.96	32.80	17.11	22.25	10.34	10.35	14.58	-1.08	0.58	0.98	-13.25	23.77
	-0.58	-0.24	-5.15	-5.85	0.00	0.00	215.88	0.00	0.00	0.00	386.59	0.00
	43.38	32.56	11.96	16.39	10.34	10.35	230.46	-1.08	0.58	0.98	373.34	23.77
	9.23	7.99	-3.15	4.00	2.30	1.71	8.19	1.08	0.18	0.03	134.47	4.25
	34.22	24.68	15.11	9.54	7.99	8.78	222.27	0.01	0.41	0.94	238.87	19.42
	3.94	2.84	1.81	1.17	1.00	1.28	32.96	—	0.07	0.16	40.42	3.29
Key metrics
	52.48	40.85	22.52	25.90	19.34	18.18	211.14	-0.72	1.21	1.40	397.48	58.38
	21.80%	21.30%	13.30%	17.20%	12.70%	11.90%	152.70%	-8.30%	10.10%	4.20%	101.10%	20.30%
	14.20%	12.90%	8.90%	6.30%	5.20%	5.70%	160.80%	0.10%	3.40%	2.80%	60.70%	6.80%
	3.00%	—	1.00%	—	0.90%	—	16.70%	—	—	—	—	—
	57.50%	25.40%	22.80%	1,641.90%	1,176.30%	360.40%	-64.90%	-97.00%	—	—	—	—
	328.30%	181.10%	-93.20%	95,300.00%	1,848.80%	834.00%	-6.90%	-99.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	752.55	641.29	561.71	1,281	1,207	1,039
	45.05	46.97	81.38	45.37	33.50	42.71
	797.61	688.26	643.10	1,326	1,241	1,081
	681.51	628.21	608.50	1,131	1,128	1,069
	314.86	271.74	224.20	599.06	657.46	565.00
	46.75	37.66	70.80	25.33	10.46	1.06
	146.70	137.98	117.52	152.81	135.84	114.35
	5.15	1.41	2.92	51.10	92.17	95.53
	32.31	30.61	24.48	53.30	57.36	131.04
	185.64	175.77	175.63	212.42	186.69	—
	116.12	60.05	34.59	195.17	113.17	12.53
	-11.82	-11.01	223.20	386.59	-26.65	0.00
	104.29	49.05	257.80	581.76	86.52	12.53
	18.07	7.73	7.27	151.27	38.69	14.68
	83.55	41.42	250.48	420.96	47.60	-2.15
	9.76	4.95	37.25	71.24	8.06	-0.36
Key metrics
	141.75	81.07	285.20	686.16	236.05	239.10
	18.84%	12.60%	50.80%	53.60%	19.60%	23.00%
	11.10%	6.50%	44.60%	32.90%	3.90%	-0.20%
	—	3.60%	21.40%	—	—	—
	66.39%	14.20%	-56.10%	6.10%	16.20%	—
	-65.05%	-83.50%	-40.50%	784.40%	2,314.00%	—
	—	-150.90	-89.88	—	—	—
	—	-1.53	-0.10	—	—	—
	—	0.01	0.03	—	—	—
	—	-411.94	-387.42	—	—	—
	—	114.2	109.5	—	—	—
Balance sheet
	—	1,673	1,438	—	—	—
	—	976.75	865.35	—	—	—
	—	429.85	428.04	—	—	—
	—	198.55	164.52	—	—	—
	—	147.93	114.18	—	—	—
	—	158.42	105.01	—	—	—
	—	275.14	260.07	—	—	—
	—	145.86	110.23	—	—	—
	—	254.70	220.58	—	—	—
	—	17.91	40.62	—	—	—
	—	5.61	14.91	—	—	—
	—	12.30	25.71	—	—	—
	—	1,384	1,173	—	—	—
Cash flow
	—	-63.18	-25.47	—	—	—
	—	-72.68	-109.62	—	—	—
	—	141.81	69.20	—	—	—
	—	87.72	64.41	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	234.89	186.08	172.70	149.48	150.44	148.00	144.75	1.41	2.71	30.46	381.73	276.28
	7.60	7.63	2.21	27.58	17.86	14.58	4.41	13.81	12.95	11.14	25.25	7.11
	242.49	193.71	174.91	177.06	168.30	162.58	149.16	15.22	15.65	41.60	406.98	283.40
	201.67	161.05	158.04	153.59	157.24	152.75	138.89	10.58	15.33	35.41	310.42	257.07
	92.86	81.73	78.24	66.14	65.91	64.45	31.77	—	—	—	128.83	153.36
	16.05	13.27	7.26	9.85	11.89	8.66	33.91	0.37	0.50	25.18	21.20	1.76
	37.36	38.95	37.20	31.39	35.73	32.00	30.79	6.16	5.22	5.56	38.50	35.68
	1.33	0.71	-2.44	0.67	2.01	1.15	-26.76	0.11	0.41	0.17	11.48	21.05
	7.77	7.58	8.08	8.84	6.98	6.68	7.44	0.25	0.22	0.25	12.67	13.56
	49.16	38.59	50.33	42.56	35.28	41.66	57.51	—	8.99	4.25	76.73	40.66
	40.82	32.66	16.87	23.47	11.06	9.83	10.27	4.64	0.32	6.19	96.56	26.33
	-0.58	-0.24	-5.15	-5.85	0.00	0.00	215.88	—	—	—	386.59	—
	40.24	32.43	11.72	17.61	11.06	9.83	226.15	4.64	0.32	6.19	483.15	26.33
	9.21	7.98	-3.22	4.00	2.30	1.71	8.06	—	—	—	133.56	4.67
	31.03	24.44	14.94	10.74	8.76	8.12	218.09	4.64	0.32	6.19	349.59	21.66
	3.57	2.81	1.79	1.32	1.10	1.18	32.34	0.78	0.05	1.05	59.17	3.66
Key metrics
	49.34	40.72	17.36	27.12	20.05	17.66	206.83	5.00	0.95	6.61	507.30	60.94
	21.00%	21.90%	10.10%	18.10%	13.30%	11.90%	142.90%	354.60%	35.10%	21.70%	132.90%	22.10%
	13.20%	13.10%	8.70%	7.20%	5.80%	5.50%	150.70%	329.10%	11.80%	20.30%	91.60%	7.80%
	2.80%	—	0.70%	—	1.00%	—	16.50%	—	—	—	—	—
	56.10%	25.70%	19.30%	10,501.40%	5,451.30%	385.90%	-62.10%	-99.50%	—	—	—	—
	254.20%	201.00%	-93.10%	131.50%	2,637.50%	31.20%	-37.60%	-78.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	743.15	635.89	549.65	1,227	1,152	988.09
	45.02	46.96	81.28	45.31	33.28	41.72
	788.17	682.84	630.92	1,273	1,185	1,030
	674.35	621.62	589.98	1,082	1,079	1,020
	318.97	274.74	224.56	561.18	618.72	525.73
	46.43	37.66	70.80	25.33	10.46	1.06
	144.90	136.33	115.33	148.88	132.70	111.88
	0.27	1.40	2.92	51.10	92.17	95.53
	32.27	30.57	24.48	53.30	57.36	130.97
	180.64	169.83	162.25	204.89	180.33	—
	113.82	61.22	40.94	190.88	105.85	9.69
	-11.82	-11.01	223.20	386.59	-26.65	-1.69
	102.00	50.22	264.14	577.47	79.20	8.00
	17.97	7.66	8.06	169.86	36.73	13.71
	81.15	42.56	256.09	418.39	42.47	-5.71
	9.49	5.09	38.08	70.81	7.19	-0.97
Key metrics
	134.54	82.19	291.54	681.87	228.73	234.50
	18.10%	12.90%	53.00%	55.60%	19.90%	23.70%
	10.92%	6.70%	46.60%	34.10%	3.70%	-0.60%
	—	3.70%	22.10%	—	—	—
	67.15%	15.70%	-55.20%	6.50%	16.60%	—
	-66.13%	-83.40%	-38.80%	885.10%	843.80%	—
	—	-127.91	-103.56	—	—	—
	—	-0.94	-0.15	—	—	—
	—	0.01	0.03	—	—	—
	—	-397.27	-375.85	—	—	—
	—	107.8	104.2	—	—	—
Balance sheet
	—	1,654	1,422	—	—	—
	—	874.91	793.73	—	—	—
	—	414.99	413.01	—	—	—
	—	188.77	160.23	—	—	—
	—	142.98	107.25	—	—	—
	—	86.16	59.64	—	—	—
	—	275.14	258.84	—	—	—
	—	144.01	110.46	—	—	—
	—	251.55	216.35	—	—	—
	—	17.72	37.16	—	—	—
	—	5.61	14.62	—	—	—
	—	12.11	22.54	—	—	—
	—	1,371	1,164	—	—	—
Cash flow
	—	-40.19	-39.15	—	—	—
	—	-100.16	-109.67	—	—	—
	—	145.26	74.22	—	—	—
	—	87.72	64.41	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -17.97%
Sales CAGR 5Y: —
Profit CAGR 3Y: +0.07%
Profit CAGR 5Y: —
Sales YoY (TTM): +67.15%
Profit YoY (TTM): -66.13%

Consolidated

Sales CAGR 3Y: -19.01%
Sales CAGR 5Y: —
Profit CAGR 3Y: -4.53%
Profit CAGR 5Y: —
Sales YoY (TTM): +66.39%
Profit YoY (TTM): -65.05%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 42.93%

Quarter	September 2026	June 2026
Promoter %	42.93%	42.93%

Holder	Type	Holding	Previous	Change
ESSIX BIOSCIENCES LIMITED	Promoter	37.81%	37.81%	0.00%
ZEAL GLOBAL OPPORTUNITIES FUND	Public	4.62%	4.62%	0.00%
NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE	Public	3.32%	3.24%	+0.08%
PANCHKULA FINVEST PRIVATE LIMITED	Public	2.48%	2.48%	0.00%
ASHOKKUMAR CHANDAK	Public	2.42%	2.39%	+0.03%
ZAKI ABBAS NASSER	Public	2.00%	2.00%	0.00%
PRANAV JONEJA	Public	1.44%	1.44%	0.00%
ARK GLOBAL EMERGING COMPANIES, LP	Public	1.40%	1.62%	-0.22%
SHARWAN SINGH GULERIA	Public	1.32%	1.30%	+0.02%
NAVRATTAN MUNJAL	Promoter	1.16%	1.16%	0.00%
RAMESHKUMAR JAVERCHAND JAIN	Public	1.14%	1.16%	-0.02%
RISHAV MEHTA	Promoter	1.10%	1.10%	0.00%
CHETAN CHANDAK	Public	1.04%	1.04%	0.00%
NISARG AJAYKUMAR VAKHARIA	Public	1.04%	1.04%	0.00%
MANISH CHANDAK	Public	1.01%	1.01%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Ind-Swift Laboratories Ltd.	3,232	371.65	38.68	3.60%	+66.39% TTM	-65.05% TTM	+265.08%

Filings & corporate actions

Recent announcements

Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026.4 Nov 2026 · Company Update / Analyst / Investor Meet
Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 20264 Nov 2026 · Company Update / Investor Presentation
Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants3 Nov 2026 · Company Update / Monitoring Agency Report
Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants3 Nov 2026 · Company Update / Monitoring Agency Report
Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter ....30 Oct 2026 · Company Update / Analyst / Investor Meet
Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 202630 Oct 2026 · Company Update / Press Release / Media Release
Please refer attached pdf29 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Please refer attached pdf29 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Please find enclosed copy of financial results29 Oct 2026 · Result / Financial Results
Please find enclosed outcome of the Board Meeting held on October 29, 202629 Oct 2026 · Board Meeting / Outcome of Board Meeting
Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve inter alia, to Consider ....15 Oct 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others12 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please refer attached pdf.12 Oct 2026 · Company Update / General
Please find outcome of Preferential Issue Committee Meeting held on Oct. 08, 20268 Oct 2026 · Corp Action / Conversion of Securities
Please find enclosed newspaper clippings informing stakeholders regarding special window for relodgement of physical shares6 Oct 2026 · Company Update / Newspaper Publication
Please find enclosed scrutiniser''s report along with voting results for the 31st AGM, held on 30th September, 20265 Oct 2026 · AGM/EGM / AGM
Please refer the attached pdf5 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed proceedings of the 31st Annual General Meeting of the company held on Wednesday, 30th Sept., 2026.30 Sep 2026 · AGM/EGM / AGM
Please refer attached pdf28 Sep 2026 · Company Update / General
Please refer the attached pdf.28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed Schedule of Analyst / Investor Meet scheduled to be held on Tuesday, 29th September, 2026, at 01.00 P.M. IST23 Sep 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others22 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please refer attached pdf.21 Sep 2026 · Company Update / General
Outcome of Preferential Issue Committee for Allotment of 70,00,000 Fully Convertible Warrants on Preferential Basis17 Sep 2026 · Company Update / Allotment of Equity Shares
Please refer enclosed pdf.6 Sep 2026 · Company Update / Newspaper Publication
Please find enclosed Annual Report for the FY 2025-26.5 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 31st AGM of the company scheduled to be held on Wednesday, 30.09.2026, at 03:00 P.M. through VC/OAVM.5 Sep 2026 · AGM/EGM / AGM
Please refer attached newspaper publication dated 04.09.2026.4 Sep 2026 · Company Update / Newspaper Publication
Please refer attached pdf.4 Sep 2026 · Company Update / General
Please find enclosed outcome of Board Meeting held on September 02, 2026.2 Sep 2026 · Others / Outcome without intimation
Please refer attached pdf regarding clarification sought from company regarding movement in value .27 Aug 2026 · Company Update / General
The Exchange has sought clarification from Ind-Swift Laboratories Ltd on August 27, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.27 Aug 2026 · Company Update / Clarification
Please find enclosed Transcript of Earning Call held on August 17, 2026.20 Aug 2026 · Company Update / Earnings Call Transcript
Please find enclosed press release titled as Ind-Swift to make Jammu facility EUGMP and PICS Compliant targets additional revenue of 100 crores from 2029-30 onwards .18 Aug 2026 · Company Update / Press Release / Media Release
Audio recording of earning conference call held on 17.08.2026 on un-audited financial results for the quarter ended 30.06.2026.17 Aug 2026 · Company Update / General
Please find attached intimation regarding the investor presentation on un-audited financial results for the quarter ended June, 30 2026.17 Aug 2026 · Company Update / Investor Presentation
Please find enclosed Schedule of Analyst / Investor Meet will be held on Monday, 17th August, 2026, at 03.00 P.M. IST in respect of financial results of the Company for the quarter ended ....12 Aug 2026 · Company Update / Analyst / Investor Meet
Please find enclosed report of the Monitoring Agency for the quarter ended June 30, 2026.12 Aug 2026 · Company Update / Monitoring Agency Report
Please refer attached pdf .12 Aug 2026 · Company Update / Press Release / Media Release
please refer attached pdf.10 Aug 2026 · Result / Financial Results

Board meetings

29 Oct 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results